A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2020
Price : $35 *
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 28 Jul 2019 Planned End Date changed from 20 Sep 2019 to 16 Mar 2020.
- 28 Jul 2019 Planned primary completion date changed from 20 Sep 2019 to 16 Mar 2020.
- 28 Jul 2019 Planned initiation date changed from 23 Jul 2019 to 15 Jan 2020.